As­traZeneca and Dai­ichi Sankyo sprint to mar­ket af­ter FDA clears En­her­tu in just two weeks

Reg­u­la­tors didn’t keep As­traZeneca and Dai­ichi Sankyo wait­ing long at all for their lat­est En­her­tu ap­proval.

The part­ners pulled a win on Fri­day in HER2-low breast can­cer pa­tients who’ve al­ready failed on chemother­a­py, less than two weeks af­ter its sup­ple­men­tal BLA was ac­cept­ed. While this isn’t the FDA’s fastest ap­proval — Bris­tol My­ers Squibb won an OK for its block­buster check­point in­hibitor Op­di­vo in just five days back in March — it comes well ahead of En­her­tu’s orig­i­nal Q4 PDU­FA date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER